MedTrace Logo

Survival and Recurrence After ABO-Incompatible Living Donor Liver Transplantation for Hepatocellular Carcinoma

NCT07703735 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 371

Last updated 2026-07-14

No results posted yet for this study

Summary

This retrospective cohort study aimed to evaluate long-term oncologic outcomes after ABO-incompatible living donor liver transplantation (LDLT) for hepatocellular carcinoma (HCC). Patients who underwent LDLT between January 2012 and December 2023 at a single tertiary center were included. Outcomes of interest included overall survival and recurrence patterns, with a focus on differences in time to recurrence between ABO-compatible and ABO-incompatible recipients.

Conditions

  • Liver Transplantation
  • Hepatocellular Carcinoma (HCC)

Sponsors & Collaborators

  • Seoung Hoon Kim

    lead OTHER_GOV

Principal Investigators

  • Seoung Hoon Kim, MD, PhD · National Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-01
Primary Completion
2025-12-31
Completion
2026-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07703735 on ClinicalTrials.gov